When we designed the present study, we anticipated an improvement in the low percentages of Vδ2+Vγ9+ γδ T cells observed in untreated MS [10] by IFN-β treatment; however, we unexpectedly found that IFN-β increased Vδ1−Vδ2−Vγ9− cell percentages in γδ T cells but did not reverse the decrease of Vδ2+Vγ9+ cells nor the loss of a positive correlation between Vδ2+Vγ9+ γδ T cells and Treg cells seen in HCs. The gene discussed is IFNB1; the disease is myeloid sarcoma.